Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.24M | 1.04M | 581.00K | 375.00K | 137.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24M | 1.04M | 581.00K | 375.00K | 137.00K |
| Cost of Revenue | 556.00K | 55.00K | 29.00K | 20.00K | 11.00K |
| Gross Profit | 686.00K | 983.00K | 552.00K | 355.00K | 126.00K |
| SG&A Expenses | 94.57M | 87.28M | 79.79M | 69.11M | 62.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 201.88M | 196.53M | 179.95M | 160.03M | 133.03M |
| Operating Income | -200.64M | -195.50M | -179.37M | -159.65M | -132.89M |
| Income Before Tax | -211.61M | -202.92M | -187.08M | -165.76M | -137.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -211.61 | -202.92 | -187.08 | -165.76 | -137.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -211.61M | -202.92M | -187.08M | -165.76M | -137.07M |
| EBIT | -200.64M | -195.50M | -179.37M | -159.65M | -132.89M |
| EBITDA | -200.32M | -195.17M | -179.04M | -159.33M | -132.57M |
| EPS Basic | -7.36 | -7.12 | -6.64 | -5.92 | -4.90 |
| Normalized Basic EPS | -4.51 | -4.45 | -4.15 | -3.70 | -3.06 |
| EPS Diluted | -7.36 | -7.12 | -6.64 | -5.92 | -4.90 |
| Normalized Diluted EPS | -4.51 | -4.45 | -4.15 | -3.70 | -3.06 |
| Average Basic Shares Outstanding | 115.14M | 113.89M | 112.70M | 112.06M | 111.97M |
| Average Diluted Shares Outstanding | 115.14M | 113.89M | 112.70M | 112.06M | 111.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |